Skip to main content
Signal8

ENZB (ENZB)

Enzo Biochem, Inc. logo

Enzo Biochem, Inc.

OTC:ENZBHealthcare
Mkt Cap-
Float-
O/S-
Inst Own-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap--
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.

SectorHealthcare
IndustryMedical - Diagnostics & Research
ExchangeOTC
CountryUSUS
IPO Date-
Shares Outstanding-
Float--
Company Overview

Enzo Biochem, Inc. operates as an integrated entity encompassing diagnostics, clinical laboratory services, and life sciences.

The company is dedicated to developing, manufacturing, and commercializing diagnostic and research products, fundamentally rooted in genetic engineering, biotechnology, and molecular biology.

Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division focuses on creating, producing, and distributing essential products and tools for clients engaged in clinical research, pharmaceutical development, and broader bioscience investigations.

Its extensive portfolio comprises proteins, antibodies, peptides, small molecules, labeling probes, dyes, and various kits. These offerings empower life science researchers in areas such as target identification and validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also serves scientific experts researching a wide array of health issues, including cancer, cardiovascular disorders, neurological diseases, diabetes and obesity, endocrine imbalances, infectious and autoimmune conditions, hepatotoxicity, and renal injury. Through its Clinical Laboratory Services segment, Enzo Biochem provides a spectrum of molecular and other clinical laboratory tests and procedures. These are utilized in routine patient care by medical professionals to aid in establishing or corroborating diagnoses, monitoring treatment efficacy or medication levels, and uncovering previously undiagnosed conditions. This segment operates a full-scale clinical laboratory in Farmingdale, New York, supported by a network of 30 patient service centers throughout New York and New Jersey. Furthermore, it manages specialized "STAT" or rapid response laboratories in New York City and Connecticut, along with a complete phlebotomy center and an internal logistics department. The Therapeutics segment is committed to devising innovative solutions for gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem promotes its products and services globally through a dedicated direct sales force and an established network of distributors.

The company was founded in 1976 and maintains its corporate headquarters in New York, New York.

Leadership

Employees

--

Country

US

Sector

Healthcare

Website

enzo.com

Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
InsiderTypeShares
Radoff Bradley Louis profile photoRadoff Bradley LouisWithholding/Transfer4.53M
Radoff Bradley Louis profile photoRadoff Bradley LouisWithholding/Transfer430.0K
PULLY STEVEN J profile photoPULLY STEVEN JWithholding/Transfer240.0K
Eckert Patricia profile photoEckert PatriciaWithholding/Transfer28.3K
COUCHMAN JONATHAN profile photoCOUCHMAN JONATHANWithholding/Transfer142.9K
COUCHMAN JONATHAN profile photoCOUCHMAN JONATHANWithholding/Transfer130.0K
Shareholders
--
Institutional
(0)
--
Insiderⓘ
(3)
--
5%+ Owners
(0)
--
Unattributed (incl. retail)ⓘ
Top Shareholders
NameShares%
Radoff Bradley Louis profile photo
Radoff Bradley Louis
Director
4.5M--
PULLY STEVEN J profile photo
PULLY STEVEN J
Director
240.0K--
COUCHMAN JONATHAN profile photo
COUCHMAN JONATHAN
Director
142.9K--
Sources: Form 4, 13D/13G
Insiders & Institutional Holders

Insiders

52-Week Range
Volume
Average Daily Volume--

30d Avg

--

60d Avg

--

90d Avg

--

Earnings
Dividend History
TTM Yield
--
Annual (LTM)
--
Latest
$0.1000
Nov 15, 24
5Y Growth
--
Compliance Status
Loading compliance data...